Boardroom Alpha
Boardroom Alpha
ACH · Current Report (Form 8-K) · Filed December 8, 2025

Accendra Health Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 8, 2025
Period
Dec 4, 2025
Ticker
ACH
Accession
0001193125-25-310528
Boardroom Alpha · Filing insights

Perry Bernocchi promoted to COO; CHRO Jennifer Stone departs; HR duties shift to GC Heath Galloway.

About Accendra Health Inc
Market cap
$217M
1Y TSR
−58.7%
3Y TSR
−45.9%
Board grade
C-
Sector
Healthcare
CEO
Edward A Pesicka
Last annual meeting: May 14, 2026 · View full Accendra Health Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 4, 2025

 

 

Owens & Minor, Inc.

(Exact name of Registrant as specified in charter)

 

 

 

Virginia   001-09810   54-1701843
(State or other jurisdiction
of incorporation)
  (Commission
file number)
  (I.R.S. employer
identification no.)

 

10900 Nuckols Road, Suite 400  
Glen Allen, Virginia   23060
(Address of principal executive offices)   (Zip code)

 

Post Office Box 27626,  
Richmond, Virginia   23261-7626
(Mailing address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code (804) 723-7000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $2 par value per share   OMI   New York Stock Exchange

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.

Appointment of Perry A. Bernocchi as Executive Vice President, Chief Operating Officer

On December 4, 2025, Owens & Minor, Inc. (the “Company”) appointed Perry A. Bernocchi, age 67, Executive Vice President, Chief Operating Officer of the Company, effective December 5, 2025. Since March 2023, Mr. Bernocchi has served as Executive Vice President and Chief Executive Officer of the Company’s Patient Direct segment. Biographical information regarding Mr. Bernocchi is set forth in the Company’s annual report on Form 10-K, filed with the U.S. Securities and Exchange Commission on February 28, 2025, and such information is incorporated by reference herein.

Mr. Bernocchi’s compensation and the terms of his employment with the Company remain unchanged. Mr. Bernocchi is not a party to any transaction, and there is no currently proposed transaction with Mr. Bernocchi, that is required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Mr. Bernocchi and any of the Company’s directors or executive officers. Mr. Bernocchi is not a party to any arrangement or understanding regarding his selection as an officer.

Item 7.01. Regulation FD Disclosure.

Effective December 31, 2025, Jennifer Stone, Executive Vice President, Chief Human Resources Officer (CHRO), will leave the Company. Upon Ms. Stone’s departure, the CHRO position will be eliminated, and Heath Galloway, Executive Vice President, General Counsel & Corporate Secretary, will add oversight of the human resources function to his current responsibilities.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 8, 2025

 

Owens & Minor, Inc.
By:  

/s/ Heath Galloway

Name:   Heath Galloway
Title:  

Executive Vice President, General Counsel

and Corporate Secretary

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Accendra Health Inc (ACH)

Reference

Frequently asked questions

When did Accendra Health Inc file this 8-K?
Accendra Health Inc (ACH) filed this Current Report (Form 8-K) with the SEC on December 8, 2025. The accession number assigned by EDGAR is 0001193125-25-310528.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Perry Bernocchi promoted to COO; CHRO Jennifer Stone departs; HR duties shift to GC Heath Galloway. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Accendra Health Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Accendra Health Inc has filed under CIK 75252, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer